2002PubMedRequires access

[Female sexual dysfunction as adverse effect of pharmacological treatment].

Annamaria Giraldi, Jette Victor

Open publisher page 3 citations

Abstract

This review describes female sexual dysfunction (FSD) as an adverse effect to pharmacological treatment. FSD covers libido, arousal, orgasm, and pain problems. The existing knowledge of the influence of medication upon female sexual function is very sparse. Treatment with SSRIs and other antidepressants may cause decreased libido and organism problems. Antipsychotic treatment often causes libido, lubrication, and orgasm problems. Spironolactone may cause decreased libido and impaired lubrication. Whether antihypertensives, H2-receptor antagonists and sex hormones have sexual adverse effects has not been clarified properly. Some drugs, such as bupropion and sildenafil, may enhance the sexual function, but further studies have to be carried out. The need for further research on the topic is stressed.

About this research paper

What this paper is about

This review describes female sexual dysfunction (FSD) as an adverse effect to pharmacological treatment. FSD covers libido, arousal, orgasm, and pain problems. The existing knowledge of the influence of medication upon female sexual function is very sparse. Treatment with SSRIs and other antidepressants may cause decreased libido and organism problems. Antipsychotic treatment often causes libido, lubrication, and orgasm problems. Spironolactone may cause decreased libido and impaired lubrication. Whether antihypertensives, H2-receptor antagonists and sex hormones have sexual adverse effects has not been clarified properly. Some drugs, such as bupropion and sildenafil, may enhance the sexual function, but further studies have to be carried out. The need for further research on the topic is stressed.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This review describes female sexual dysfunction (FSD) as an adverse effect to pharmacological treatment. FSD covers libido, arousal, orgasm, and pain problems. The existing knowledge of the influence of medication upon female sexual function is very sparse. Treatment with SSRIs and other antidepressants may cause decreased libido and organism problems. Antipsychotic treatment often causes libido, lubrication, and orgasm problems. Spironolactone may cause decreased libido and impaired lubrication. Whether antihypertensives, H2-receptor antagonists and sex hormones have sexual adverse effects has not been clarified properly. Some drugs, such as bupropion and sildenafil, may enhance the sexual function, but further studies have to be carried out. The need for further research on the topic is stressed.

Key concepts: Libido, Orgasm, Sexual dysfunction, Decreased Libido, Adverse effect, Hypoactive sexual desire disorder, Sexual function, Female sexual dysfunction

Related papers

Back to paper searchBrowse research topicsOriginal source
[Female sexual dysfunction as adverse effect of pharmacological treatment]. — Research Paper | ScholarLens